Tiofosfamid

Tiofosfamid (thiotepa, Thiophosphamidum; list a) - antineoplastic. Used in cancer of the ovary, breast, inoperable cervical cancer, mesothelioma of the peritoneum, as well as chronic lymphocytic leukemia, Hodgkin's lymphoma, chronic myelogenous leukemia (in the form of leukemia), retikulosarkome, lymphosarcoma.
Tiofosfamid assign inside to 0.01-0.02 g a day (3 times a week), at an average rate of 0.15-0.25 g, and intramuscularly or intravenously at 0.01 g, in the first days or every day, in the next 2 to 5-7-14 days of treatment from 0.1 to 0.3 g
Released in sealed bottles, containing 0.01 and 0.02 g tiofosfamida in the form of a powder for preparation of solution are ex tempore) or tablets. Cm. also Antitumor agents.